The specifications of excipients are important to pharmaceutical manufacturers to ensure that the final product can be manufactured robustly over the entire lifecycle of a drug product. Particle size specifications are key for dry powder inhalation excipients and they should be agreed between users and suppliers. The current paper evaluates two development strategies to set particle size specifications. It is shown that the application of quality-by-design principles to specification setting could result in broader specifications, while it guarantees that efficacy, safety and manufacturing of the medication is not affected. A multitude of reasons exist to keep specifications broader than the production capability range, including improved risk-mitigation and potentially reduced regulatory challenges during and after registration.
Keywords: Excipients; Formulation; Inhalation; Interactive mixtures; Lung drug delivery; Particle size; Physical characterization; Pulmonary drug delivery.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.